News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRANSGENE (ENX:TNG) Announces Plans For A Phase 1b/2 Trial With Pexa-Vec In Advanced Solid Tumors



2/25/2014 9:20:52 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) today announced plans for a Phase 1b/2 trial with Pexa-Vec that is to be funded by the Institut National du Cancer (INCa). This trial will be part of an INCa-funded program called CLIP², that is facilitating patient access to innovative treatments and promoting global exchanges in cutting edge research that involve academic-initiated research and novel therapies being developed by biotechnology and pharmaceutical companies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES